Hepatocellular carcinoma in transfusion dependent thalassemia patients: a review from a clinical perspective

Abstract

Survival in patients with transfusion-dependent thalassemias (TDT) has increased, and complications such as hepatocellular carcinoma (HCC) are emerging. Risk factors include viral infection, mainly hepatitis C virus (HCV), iron overload, the presence of cirrhosis, and immune dysregulation. Median survival after HCC occurrence has been estimated at 12 months, while data regarding the incidence of HCC in this population are minimal. Implementing effective hepatitis B virus (HBV)/HCV antiviral treatment and universal HBV vaccination programs is expected to decrease the risk for hepatocarcinogenesis substantially. Significant hemosiderosis and hepatic fibrosis are common in patients with TDT despite chelation therapy and have been correlated with HCC development. Thus, iron overload should be monitored with liver iron concentration and ferritin levels, and effective chelation therapy should be applied. In addition, all TDT patients, particularly those with cirrhosis, should be under surveillance every six months with abdominal ultrasound ± alpha-fetoprotein levels, as this combination seems to provide better sensitivity for early HCC detection.

Keywords

Transfusion-dependent thalassemias / hepatocellular carcinoma / hepatitis B virus / hepatitis C virus / iron overload / liver iron concentration / liver stiffness measurement

References

[1] Camaschella C.Ineffective erythropoiesis and regulation of iron status in iron loading anaemias.Br J Haematol2016;172:512-23

[2] Vichinsky E,Trimble S.CDC Thalassemia InvestigatorsTransfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention (CME).Transfusion2014;54:972-81; quiz 971 PMCID:PMC4410835

[3] Marsella M.Thalassemia and hepatocellular carcinoma: links and risks.J Blood Med2019;10:323-34 PMCID:PMC6756274

[4] Mancuso A.Evidence-based medicine and management of hepatocellular carcinoma in Thalassemia.BMC Gastroenterol2020;20:409 PMCID:PMC7724702

[5] Mangia A,Cillo U.Hepatocellular carcinoma in adult thalassemia patients: an expert opinion based on current evidence.BMC Gastroenterol2020;20:251 PMCID:PMC7398335

[6] Bray F,Soerjomataram I,Torre LA.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2018;68:394-424

[7] McGlynn KA,El-Serag HB.Epidemiology of hepatocellular carcinoma.Hepatology2021;73 Suppl 1:4-13 PMCID:PMC7577946

[8] Singal AG,Nahon P.Epidemiology and surveillance for hepatocellular carcinoma: new trends.J Hepatol2020;72:250-61 PMCID:PMC6986771

[9] Llovet JM,Villanueva A.Hepatocellular carcinoma.Nat Rev Dis Primers2021;7:6

[10] Cancer stat facts: liver and intrahepatic bile duct cancer. Available from: https://seer.cancer.gov/statfacts/html/livibd.html [Last accessed on 25 Nov 2021]

[11] Borgna-Pignatti C,Lombardo T.Hepatocellular carcinoma in the thalassaemia syndromes.Br J Haematol2004;124:114-7

[12] Borgna-Pignatti C,Forni GL.Hepatocellular carcinoma in thalassaemia: an update of the Italian Registry.Br J Haematol2014;167:121-6

[13] Kourakli A,Skafidas M.Hepatitis C virus infection, but not hepatic iron overload is the dominant risk factor for the manifestation of hepatocellular carcinoma among Greek thalassemic patients.Blood2018;132:2347

[14] Fragatou S,Manesis G.Incidence of hepatocellular carcinoma in a thalassemia unit.Hemoglobin2010;34:221-6

[15] Papadopoulos N,Malagari K,Theochari M.Characteristics and prognosis of hepatocellular carcinoma in multi-transfused patients with β-thalassemia. Experience of a single tertiary center.Mediterr J Hematol Infect Dis2020;12:e2020013 PMCID:PMC7059739

[16] Mancuso A,Renda MC.A prospective study of hepatocellular carcinoma incidence in thalassemia.Hemoglobin2006;30:119-24

[17] De Sanctis V,Daar S.A concise review on the frequency, major risk factors and surveillance of hepatocellular carcinoma (HCC) in β-thalassemias: past, present and future perspectives and the ICET-A experience.Mediterr J Hematol Infect Dis2020;12:e2020006 PMCID:PMC6951357

[18] Mancuso A.Hepatocellular carcinoma in thalassemia: a critical review.World J Hepatol2010;2:171-4 PMCID:PMC2999281

[19] Finianos A,Taher A.Hepatocellular carcinoma in β-thalassemia patients: review of the literature with molecular insight into liver carcinogenesis.Int J Mol Sci2018;19:4070 PMCID:PMC6321074

[20] Aydinok Y,Piga A.Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: results from the CORDELIA study.Eur J Haematol2015;95:244-53

[21] Pok S,Wong HJ.Testosterone regulation of cyclin E kinase: a key factor in determining gender differences in hepatocarcinogenesis.J Gastroenterol Hepatol2016;31:1210-9

[22] Akinyemiju T,Ahmed M.Global Burden of Disease Liver Cancer CollaborationThe burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015.JAMA Oncol2017;3:1683-91 PMCID:PMC5824275

[23] Fattovich G,Donato F.Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors.J Hepatol2008;48:335-52

[24] Huang YT,Yang HI.Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C.J Clin Oncol2011;29:3643-50 PMCID:PMC4874144

[25] Ghouri YA,Rowe JH.Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis.J Carcinog2017;16:1 PMCID:PMC5490340

[26] Papatheodoridis G,Sypsa V.PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.J Hepatol2016;64:800-6

[27] Chien YC,Kuo HS.Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched.Epidemiol Rev2006;28:126-35

[28] Franco E,Marino MG,Serino L.Hepatitis B: epidemiology and prevention in developing countries.World J Hepatol2012;4:74-80 PMCID:PMC3321493

[29] European Association for the Study of the Liver, Electronic address: [e-mail], European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.J Hepatol2017;67:370-98

[30] Di Marco V,Gagliardotto F.Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C.Haematologica2008;93:1243-6

[31] Triantos C,Kalafateli M.Hepatitis C in patients with β-thalassemia major. A single-centre experience.Ann Hematol2013;92:739-46

[32] Alavian SM,Kamran BL.Epidemiology of HCV infection among thalassemia patients in eastern Mediterranean countries: a quantitative review of literature.Iran Red Crescent Med J2010;12:365-76

[33] Koike K.Pathogenesis of HCV-associated HCC: dual-pass carcinogenesis through activation of oxidative stress and intracellular signaling.Hepatol Res2007;37 Suppl 2:S115-20

[34] Koike K.Hepatitis C virus contributes to hepatocarcinogenesis by modulating metabolic and intracellular signaling pathways.J Gastroenterol Hepatol2007;22 Suppl 1:S108-11

[35] Origa R,Filosa A.Italy for THAlassemia and hepatitis C Advance - Società Italiana Talassemie ed Emoglobinopatie (ITHACA-SITE)Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies.Am J Hematol2017;92:1349-55

[36] Raimondi S,Mondelli MU.Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis.J Hepatol2009;50:1142-54

[37] Association for the Study of the Liver, Electronic address: [e-mail], Clinical Practice Guidelines Panel: Chair:, EASL Governing Board representative, Panel members. EASL recommendations on treatment of hepatitis C: Final update of the series^☆.J Hepatol2020;73:1170-218

[38] Sinakos E,Koskinas J.Treatment of chronic hepatitis C with direct-acting antivirals in patients with β-thalassaemia major and advanced liver disease.Br J Haematol2017;178:130-6

[39] Kanwal F,Asch SM,Cao Y.Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents.Gastroenterology2017;153:996-1005.e1

[40] Forner A,Bruix J.Hepatocellular carcinoma.Lancet2018;391:1301-14

[41] Ioannou GN,Weiss NS,Beretta L.Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis.Clin Gastroenterol Hepatol2007;5:938-45, 945.e1

[42] Tarao K,Ikeda T.Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases-meta-analytic assessment.Cancer Med2019;8:1054-65 PMCID:PMC6434205

[43] Li CK,Lam CW.Liver disease in transfusion dependent thalassaemia major.Arch Dis Child2002;86:344-7 PMCID:PMC1751092

[44] European Association for the Study of the Liver, Electronic address: [e-mail]., European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma.J Hepatol2018;69:182-236

[45] Colli A,Miletic D.Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.Cochrane Database Syst Rev2021;4:CD013346 PMCID:PMC8078581

[46] Bradbear RA,Siskind V.Cohort study of internal malignancy in genetic hemochromatosis and other chronic nonalcoholic liver diseases.J Natl Cancer Inst1985;75:81-4

[47] Elmberg M,Ekbom A.Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives.Gastroenterology2003;125:1733-41

[48] Sharp P.Molecular mechanisms involved in intestinal iron absorption.World J Gastroenterol2007;13:4716-24 PMCID:PMC4611193

[49] Kountouras D,Fatourou E.Liver disease in adult transfusion-dependent beta-thalassaemic patients: investigating the role of iron overload and chronic HCV infection.Liver Int2013;33:420-7

[50] Siagris D,Christofidou M.Virological, immunological and histological aspects in adult beta-thalassemic patients with chronic hepatitis C virus infection.Liver Int2004;24:204-9

[51] Maira D,Marcon A.Progression of liver fibrosis can be controlled by adequate chelation in transfusion-dependent thalassemia (TDT).Ann Hematol2017;96:1931-6

[52] Delicou S,Tambaki M,Koskinas J.Transient elastography (TE) is a useful tool for assessing the response of liver iron chelation in sickle cell disease patients.Mediterr J Hematol Infect Dis2018;10:e2018049 PMCID:PMC6131104

[53] Angelucci E,Nicolucci A.Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation.Blood2002;100:17-21

[54] Kim E.Hepatocellular carcinoma: old friends and new tricks.Exp Mol Med2020;52:1898-907 PMCID:PMC8080814

[55] Fargion S,Fracanzani AL.Role of iron in hepatocellular carcinoma.Clin Liver Dis (Hoboken)2014;3:108-10 PMCID:PMC6448713

[56] Dixon SJ,Lamprecht MR.Ferroptosis: an iron-dependent form of nonapoptotic cell death.Cell2012;149:1060-72 PMCID:PMC3367386

[57] Li J,Yin HL.Ferroptosis: past, present and future.Cell Death Dis2020;11:88 PMCID:PMC6997353

[58] Kew MC.Hepatic iron overload and hepatocellular carcinoma.Cancer Lett2009;286:38-43

[59] Deugnier Y,Ropert M.Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years.Gastroenterology2011;141:1202-11, 1211.e1-3

[60] Kato J,Kobune M.Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C.J Gastroenterol2007;42:830-6

[61] Ba Q,Huang H.Iron deprivation suppresses hepatocellular carcinoma growth in experimental studies.Clin Cancer Res2011;17:7625-33

[62] St Pierre TG,Chua-anusorn W.Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance.Blood2005;105:855-61

[63] Porter J,Kattamis A. Chapter 3: Iron overload and chelation. Guidelines for the management of transfusion dependent thalassaemia (TDT). Nicosia (CY): Thalassaemia International Federation; 2014.

[64] Cata JP,Gottumukkala V,Sessler DI.Inflammatory response, immunosuppression, and cancer recurrence after perioperative blood transfusions.Br J Anaesth2013;110:690-701 PMCID:PMC3630286

[65] Moukhadder HM,Cappellini MD.Hepatocellular carcinoma as an emerging morbidity in the thalassemia syndromes: a comprehensive review.Cancer2017;123:751-8

[66] Farmakis D,Polymeropoulos E.Pathogenetic aspects of immune deficiency associated with beta-thalassemia.Med Sci Monit2003;9:RA19-22

[67] Shen L,He H.Crosstalk between macrophages, T Cells, and iron metabolism in tumor microenvironment.Oxid Med Cell Longev2021;2021:8865791 PMCID:PMC7889336

[68] Asare GA,Naidoo V.Synergistic interaction between excess hepatic iron and alcohol ingestion in hepatic mutagenesis.Toxicology2008;254:11-8

[69] Sekine S,Watanabe H.Mitochondrial iron accumulation exacerbates hepatic toxicity caused by hepatitis C virus core protein.Toxicol Appl Pharmacol2015;282:237-43

[70] Dongiovanni P,Fargion S.Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target.J Hepatol2011;55:920-32

[71] Valenti L,Bugianesi E.HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease.Gastroenterology2010;138:905-12